Narcolepsy and Other Central Hypersomnias
Identifieur interne : 000415 ( Hal/Corpus ); précédent : 000414; suivant : 000416Narcolepsy and Other Central Hypersomnias
Auteurs : Yves Dauvilliers ; Lucie BarateauSource :
Abstract
PURPOSE OF REVIEW: This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3). RECENT FINDINGS: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF is now theoretically sufficient to diagnose narcolepsy type 1, as it is a highly specific and sensitive biomarker. Conversely, other central hypersomnias are less well-defined disorders with variability in the phenotype, and few reliable biomarkers have been discovered so far. The epidemiologic observation that influenza A (H1N1) infection and vaccination are potential triggering factors of narcolepsy type 1 (discovered during the 2009 H1N1 pandemic) has increased interest in this rare disease, and progress is being made to better understand the process (highly suspected to be autoimmune) responsible for the destruction of hypocretin neurons. Treatment of narcolepsy remains largely symptomatic, usually initially with modafinil or armodafinil or with higher-potency stimulants such as methylphenidate or amphetamines. Several newer wake-promoting agents and psychostimulants have also been developed, including sodium oxybate, which has a role in the treatment of cataplexy and as an adjunctive wake-promoting agent, and pitolisant, a selective histamine H3 receptor inverse agonist that is currently only available in Europe. SUMMARY: Although far less common than many other sleep disorders, central hypersomnias are among the most severe and disabling diseases in the field of sleep medicine, and their early recognition is of major importance for patients, especially children, to maximize their quality of life and functioning in activities of daily living.
Url:
DOI: 10.1212/CON.0000000000000492
Links to Exploration step
Hal:hal-01760381Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Narcolepsy and Other Central Hypersomnias</title>
<author><name sortKey="Dauvilliers, Yves" sort="Dauvilliers, Yves" uniqKey="Dauvilliers Y" first="Yves" last="Dauvilliers">Yves Dauvilliers</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-139836" status="VALID"> <idno type="RNSR">201120699F</idno>
<orgName>Neuropsychiatrie : recherche épidémiologique et clinique</orgName>
<desc> <address> <addrLine>Hôpital La Colombière 39 AV Charles Flahault BP 34493 -Pav 42 Calixte Cavalier 34093 CEDEX 5 Montpellier</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-42570" type="direct"></relation>
<relation name="U1061" active="#struct-303623" type="direct"></relation>
<relation active="#struct-410122" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-42570" type="direct"><org type="institution" xml:id="struct-42570" status="OLD"> <orgName>Université Montpellier 1</orgName>
<orgName type="acronym">UM1</orgName>
<date type="end">2014-12-31</date>
<desc> <address> <addrLine>5, boulevard Henri IV - CS 19044 - 34967 Montpellier cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.univ-montp1.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="U1061" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-410122" type="direct"><org type="institution" xml:id="struct-410122" status="VALID"> <idno type="ISNI">0000000120970141</idno>
<orgName>Université de Montpellier</orgName>
<orgName type="acronym">UM</orgName>
<desc> <address> <addrLine>163 rue Auguste Broussonnet - 34090 Montpellier</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.umontpellier.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Barateau, Lucie" sort="Barateau, Lucie" uniqKey="Barateau L" first="Lucie" last="Barateau">Lucie Barateau</name>
<affiliation><hal:affiliation type="regroupinstitution" xml:id="struct-258773" status="VALID"> <orgName>Centre Hospitalier Régional Universitaire [Montpellier]</orgName>
<orgName type="acronym">CHRU Montpellier</orgName>
<desc> <address> <addrLine>191 avenue du doyen Gaston Giraud 34295 Montpellier cedex 5</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.chu-montpellier.fr</ref>
</desc>
</hal:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-01760381</idno>
<idno type="halId">hal-01760381</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01760381</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-01760381</idno>
<idno type="doi">10.1212/CON.0000000000000492</idno>
<date when="2017-08">2017-08</date>
<idno type="wicri:Area/Hal/Corpus">000415</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Narcolepsy and Other Central Hypersomnias</title>
<author><name sortKey="Dauvilliers, Yves" sort="Dauvilliers, Yves" uniqKey="Dauvilliers Y" first="Yves" last="Dauvilliers">Yves Dauvilliers</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-139836" status="VALID"> <idno type="RNSR">201120699F</idno>
<orgName>Neuropsychiatrie : recherche épidémiologique et clinique</orgName>
<desc> <address> <addrLine>Hôpital La Colombière 39 AV Charles Flahault BP 34493 -Pav 42 Calixte Cavalier 34093 CEDEX 5 Montpellier</addrLine>
<country key="FR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-42570" type="direct"></relation>
<relation name="U1061" active="#struct-303623" type="direct"></relation>
<relation active="#struct-410122" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-42570" type="direct"><org type="institution" xml:id="struct-42570" status="OLD"> <orgName>Université Montpellier 1</orgName>
<orgName type="acronym">UM1</orgName>
<date type="end">2014-12-31</date>
<desc> <address> <addrLine>5, boulevard Henri IV - CS 19044 - 34967 Montpellier cedex</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.univ-montp1.fr/</ref>
</desc>
</org>
</tutelle>
<tutelle name="U1061" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID"> <idno type="IdRef">026388278</idno>
<orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
<orgName type="acronym">INSERM</orgName>
<desc> <address> <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.inserm.fr</ref>
</desc>
</org>
</tutelle>
<tutelle active="#struct-410122" type="direct"><org type="institution" xml:id="struct-410122" status="VALID"> <idno type="ISNI">0000000120970141</idno>
<orgName>Université de Montpellier</orgName>
<orgName type="acronym">UM</orgName>
<desc> <address> <addrLine>163 rue Auguste Broussonnet - 34090 Montpellier</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.umontpellier.fr/</ref>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
<author><name sortKey="Barateau, Lucie" sort="Barateau, Lucie" uniqKey="Barateau L" first="Lucie" last="Barateau">Lucie Barateau</name>
<affiliation><hal:affiliation type="regroupinstitution" xml:id="struct-258773" status="VALID"> <orgName>Centre Hospitalier Régional Universitaire [Montpellier]</orgName>
<orgName type="acronym">CHRU Montpellier</orgName>
<desc> <address> <addrLine>191 avenue du doyen Gaston Giraud 34295 Montpellier cedex 5</addrLine>
<country key="FR"></country>
</address>
<ref type="url">http://www.chu-montpellier.fr</ref>
</desc>
</hal:affiliation>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1212/CON.0000000000000492</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"> <p>PURPOSE OF REVIEW: This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3). RECENT FINDINGS: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF is now theoretically sufficient to diagnose narcolepsy type 1, as it is a highly specific and sensitive biomarker. Conversely, other central hypersomnias are less well-defined disorders with variability in the phenotype, and few reliable biomarkers have been discovered so far. The epidemiologic observation that influenza A (H1N1) infection and vaccination are potential triggering factors of narcolepsy type 1 (discovered during the 2009 H1N1 pandemic) has increased interest in this rare disease, and progress is being made to better understand the process (highly suspected to be autoimmune) responsible for the destruction of hypocretin neurons. Treatment of narcolepsy remains largely symptomatic, usually initially with modafinil or armodafinil or with higher-potency stimulants such as methylphenidate or amphetamines. Several newer wake-promoting agents and psychostimulants have also been developed, including sodium oxybate, which has a role in the treatment of cataplexy and as an adjunctive wake-promoting agent, and pitolisant, a selective histamine H3 receptor inverse agonist that is currently only available in Europe. SUMMARY: Although far less common than many other sleep disorders, central hypersomnias are among the most severe and disabling diseases in the field of sleep medicine, and their early recognition is of major importance for patients, especially children, to maximize their quality of life and functioning in activities of daily living.</p>
</div>
</front>
</TEI>
<hal api="V3"> <titleStmt> <title xml:lang="en">Narcolepsy and Other Central Hypersomnias</title>
<author role="aut"> <persName> <forename type="first">Yves</forename>
<surname>Dauvilliers</surname>
</persName>
<idno type="halauthorid">224899</idno>
<affiliation ref="#struct-139836"></affiliation>
<affiliation ref="#struct-258773"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Lucie</forename>
<surname>Barateau</surname>
</persName>
<idno type="halauthorid">1507089</idno>
<affiliation ref="#struct-258773"></affiliation>
<affiliation ref="#struct-139836"></affiliation>
</author>
<editor role="depositor"> <persName> <forename>pascale</forename>
<surname>roussel</surname>
</persName>
<email type="md5">1692bb2fa6c060a2d7d0a4566573a94c</email>
<email type="domain">umontpellier.fr</email>
</editor>
</titleStmt>
<editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2018-04-06 11:32:51</date>
<date type="whenModified">2020-05-15 12:22:05</date>
<date type="whenReleased">2018-04-06 11:32:51</date>
<date type="whenProduced">2017-08</date>
</edition>
<respStmt> <resp>contributor</resp>
<name key="561022"> <persName> <forename>pascale</forename>
<surname>roussel</surname>
</persName>
<email type="md5">1692bb2fa6c060a2d7d0a4566573a94c</email>
<email type="domain">umontpellier.fr</email>
</name>
</respStmt>
</editionStmt>
<publicationStmt> <distributor>CCSD</distributor>
<idno type="halId">hal-01760381</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01760381</idno>
<idno type="halBibtex">dauvilliers:hal-01760381</idno>
<idno type="halRefHtml">Continuum (Minneapolis, Minn.), 2017, 23 (4, Sleep Neurology), pp.989--1004. ⟨10.1212/CON.0000000000000492⟩</idno>
<idno type="halRef">Continuum (Minneapolis, Minn.), 2017, 23 (4, Sleep Neurology), pp.989--1004. ⟨10.1212/CON.0000000000000492⟩</idno>
</publicationStmt>
<seriesStmt> <idno type="stamp" n="UNIV-MONTPELLIER">Université de Montpellier</idno>
<idno type="stamp" n="BS">Biologie-Santé</idno>
<idno type="stamp" n="U1061" corresp="INSERM">Neuropsychiatrie- Recherche épidémiologique et clinique (U1061)</idno>
</seriesStmt>
<notesStmt> <note type="audience" n="2">International</note>
<note type="popular" n="0">No</note>
<note type="peer" n="1">Yes</note>
</notesStmt>
<sourceDesc> <biblStruct> <analytic> <title xml:lang="en">Narcolepsy and Other Central Hypersomnias</title>
<author role="aut"> <persName> <forename type="first">Yves</forename>
<surname>Dauvilliers</surname>
</persName>
<idno type="halauthorid">224899</idno>
<affiliation ref="#struct-139836"></affiliation>
<affiliation ref="#struct-258773"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Lucie</forename>
<surname>Barateau</surname>
</persName>
<idno type="halauthorid">1507089</idno>
<affiliation ref="#struct-258773"></affiliation>
<affiliation ref="#struct-139836"></affiliation>
</author>
</analytic>
<monogr> <idno type="halJournalId" status="INCOMING">126193</idno>
<title level="j">Continuum (Minneapolis, Minn.)</title>
<imprint> <biblScope unit="volume">23</biblScope>
<biblScope unit="issue">4, Sleep Neurology</biblScope>
<biblScope unit="pp">989--1004</biblScope>
<date type="datePub">2017-08</date>
</imprint>
</monogr>
<idno type="doi">10.1212/CON.0000000000000492</idno>
<idno type="pubmed">28777172</idno>
</biblStruct>
</sourceDesc>
<profileDesc> <langUsage> <language ident="en">English</language>
</langUsage>
<textClass> <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
<classCode scheme="halTypology" n="ART">Journal articles</classCode>
</textClass>
<abstract xml:lang="en"> <p>PURPOSE OF REVIEW: This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3). RECENT FINDINGS: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF is now theoretically sufficient to diagnose narcolepsy type 1, as it is a highly specific and sensitive biomarker. Conversely, other central hypersomnias are less well-defined disorders with variability in the phenotype, and few reliable biomarkers have been discovered so far. The epidemiologic observation that influenza A (H1N1) infection and vaccination are potential triggering factors of narcolepsy type 1 (discovered during the 2009 H1N1 pandemic) has increased interest in this rare disease, and progress is being made to better understand the process (highly suspected to be autoimmune) responsible for the destruction of hypocretin neurons. Treatment of narcolepsy remains largely symptomatic, usually initially with modafinil or armodafinil or with higher-potency stimulants such as methylphenidate or amphetamines. Several newer wake-promoting agents and psychostimulants have also been developed, including sodium oxybate, which has a role in the treatment of cataplexy and as an adjunctive wake-promoting agent, and pitolisant, a selective histamine H3 receptor inverse agonist that is currently only available in Europe. SUMMARY: Although far less common than many other sleep disorders, central hypersomnias are among the most severe and disabling diseases in the field of sleep medicine, and their early recognition is of major importance for patients, especially children, to maximize their quality of life and functioning in activities of daily living.</p>
</abstract>
</profileDesc>
</hal>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Hal/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Corpus/biblio.hfd -nk 000415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Hal |étape= Corpus |type= RBID |clé= Hal:hal-01760381 |texte= Narcolepsy and Other Central Hypersomnias }}
![]() | This area was generated with Dilib version V0.6.34. | ![]() |